Published by
The Street
The Street
By PR Newswire SHANGHAI, Jan. 3, 2022 /PRNewswire/ — Everest Medicines Limited (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia, announced today that Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for sacituzumab govitecan (SG) in adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. The treatment was granted Ped…